Remove 2022 Remove Clinical Supply Remove Packaging
article thumbnail

Catalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities

The Pharma Data

Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch.

article thumbnail

Rapid delivery of toxicological material

Drug Target Review

However, developing an accelerated IND application requires that good laboratory practice (GLP) toxicological data must be generated, collected, interpreted and integrated in the IND-enabling data package. Therefore, there would be almost no appetite for trying to justify a change in formulation between Tox and clinical supplies.

article thumbnail

Overcoming inefficiencies to improve access to cell and gene therapy 

Drug Discovery World

Drug discovery researchers usually partner with a CDMO to provide support through the development, manufacturing, and clinical supply required to bring a drug to market. April 4, 2022. References “Approved Cellular and Gene Therapy Products.” Food and Drug Administration. link] “UPDATED: bluebird bio’s $2.8

Therapies 130